

RESEARCH ARTICLE

Three new C-27-carboxylated-lupane-triterpenoid derivatives from *Potentilla discolor* Bunge and their *in vitro* antitumor activities

Jing Zhang^{1,2}, Chao Liu², Ri-Zhen Huang¹, Hui-Feng Chen¹, Zhi-Xin Liao^{1*}, Jin-Yue Sun^{2*}, Xue-Kui Xia³, Feng-Xiang Wang⁴

1 Department of Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Southeast University, Nanjing, P. R. China, **2** Institute of Agro-Food Science and Technology/Key Laboratory of Agro-Products Processing Technology of Shandong Province, Shandong Academy of Agricultural Sciences, Jinan, P. R. China, **3** Biotechnology Center, Shandong Academy of Sciences, Jinan, P. R. China, **4** Institute of Shandong River Wetlands, Laiwu, P. R. China

* zxiao@seu.edu.cn (ZXL); moon_s731@hotmail.com (JYS)



OPEN ACCESS

Citation: Zhang J, Liu C, Huang R-Z, Chen H-F, Liao Z-X, Sun J-Y, et al. (2017) Three new C-27-carboxylated-lupane-triterpenoid derivatives from *Potentilla discolor* Bunge and their *in vitro* antitumor activities. PLoS ONE 12(4): e0175502. <https://doi.org/10.1371/journal.pone.0175502>

Editor: Salvatore V Pizzo, Duke University School of Medicine, UNITED STATES

Received: October 30, 2016

Accepted: March 26, 2017

Published: April 7, 2017

Copyright: © 2017 Zhang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This study was supported by Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Guangxi Normal University) (CMEMR2016-B06 to ZXL), the Priority Academic Program Development of Jiangsu Higher Education Institutions (No. 1107047002 to ZXL), and the Taishan Overseas

Abstract

Three new lupane-triterpenoids (**1–3**) along with six known compounds (**4–9**) were isolated from the ethanolic extract of whole plant of *Potentilla discolor* Bunge. The structures of Compounds **1–3** were established by extensive 1D and 2D NMR together with other spectrum analysis, indicating that their C-27 positions were highly oxygenated, which were rarely found in nature. Their *in vitro* anti-proliferative activities against HepG-2, MCF-7 and T-84 cell lines were evaluated by Cell Counting Kit-8 (CCK-8) assay, and the results showed different activities for three cell lines with IC₅₀ values ranging from 17.84 to 40.64 μM. In addition, the results from Hoechst 33258 and AO/EB staining as well as annexinV-FITC assays exhibited Compound **1** caused a markedly increased HepG-2 cellular apoptosis in a dose-dependent manner. The further mechanisms of Compound **1**-induced cellular apoptosis were confirmed that **1** induced the production of ROS and the alteration of pro- and anti-apoptotic proteins, which led to the dysfunction of mitochondria and activation of caspase-9 and caspase-3 and finally caused cellular apoptosis. These results would be useful in search for new potential antitumor agents and for developing semisynthetic lupane-triterpenoid derivatives with high antitumor activity.

Introduction

Potentilla is one of a hundred genera in the family Rosaceae, subfamily Rosoideae, tribe Potentilleae [1, 2], which contains about 700 species. They are widespread in temperate, arctic and Alpine zones of the Northern hemisphere. *Potentilla* species have been used in traditional medicine of different cultures by Asian, European and American for a long time [3–8]. In addition, several pharmacopoeias include monographs on *Potentilla* species, e.g. European Pharmacopoeia 9.0, 2017 [9] and Chinese Pharmacopoeia 2015 [10].

Talents Introduction Program of Shandong, China (No. tshw20120747 to JYS).

Competing interests: The authors have declared that no competing interests exist.

Potentilla discolor Bunge (PD), one of the species of *Potentilla*, is a perennial herb which abundantly distribute in China, especially in Liaoning, Anhui, Shanxi and Shandong Provinces. This plant widely grows in sparse forests, meadows, valleys and ravines, whose roots are robust, enlarged and fusiform, flowering stems erect, and pinnate leaves are oblong with margin incised dentations [11]. This species has been used traditionally in folk medicine for the treatment of diarrhea, hepatitis, functional uterine hemorrhage and traumatic hemorrhage [12, 13]. In recent years, whole herbs of PD have also been used to treat type 2 diabetes in clinical research [14–16], moreover, some scientific evidences have confirmed the effectiveness of this plant as an anticancer agent [17].

The principal phytochemicals in PD have been reported to be triterpenoids and flavonoids, besides, hydrolysable tannins, sterols, and some aromatic acids have been isolated [16, 18–21]. The ethanolic extract of PD has shown significant inhibition on the proliferation of tumor cells and the induction of cellular apoptosis at a low concentration in previous literature [17], however, there were few phytochemistry researches which focused on antitumor activities. Furthermore, triterpenoids of different structural types have been shown to be antitumor agents in a large number of reports [22–26]. All these research basics prompted us to investigate the chemical constituents of PD. As a result, three new lupane-triterpenoids were obtained from its ethanolic extract, which were rarely found in nature due to their C-27 positions were highly oxygenated [27]. In addition, six other known compounds were also obtained. Moreover, the levels of antitumor activities for the three new compounds were examined. Then, we further investigated the detailed mechanism of apoptotic effects induced by the representative Compound 1.

Materials and methods

General experimental procedures

Optical rotations were measured on a WZZ-2B spectropolarimeter. IR spectra were recorded on a NICOLET IR200 FT-IR spectrophotometer. NMR spectra were recorded on a Bruker Avance DRX-400 spectrometer at 400 MHz (^1H) and 100 MHz (^{13}C). Chemical shifts were expressed in δ (ppm) referring to TMS. HR-ESI-MS was carried out on an Agilent Technologies 6224 TOF LC-MS apparatus. Purity of compounds were determined by HPLC (Agilent 1200) on a column (Silgreen GH0525046C18A; 250 \times 4.6 mm I.D., S-5 μm , 12 nm). Apoptosis was discriminated with Beckman Coulter CytoFLEX flow cytometry.

Plant materials

Whole herbs of PD (Fig 1) were collected in a private mountain land of Mountain Tai (36° 16'N; 117° 6'E; 1532.7 m a.s.l.) owned by a local peasant, Shandong, China, in August, 2015, and got his permission to conduct this activity. PD is not an endangered or protected species, which abundantly distributes in China and is a common medicine herb in local. Besides, our collection activities didn't cause any negative impact on the local ecology. The species was identified by Dr. Chenggang Shan, Institute of Agro-Food Science and Technology, Shandong Academy of Agriculture Sciences, Jinan, China. A voucher specimen (No. 15–08–20) was deposited at nature medicine laboratory of Southeast University.

Extraction and isolation

The dried plant (5 kg) was ground into powder and then extracted with 95% ethanol (20.0 L) by heating reflux for 4 \times 3 hours using a reaction still. Following filtration and vacuum-concentration of the combined solution, it yielded a crude extract (478.8 g). 400g extract was then



Fig 1. Morphological observation of *Potentilla discolor* Bunge from Mountain Tai.

<https://doi.org/10.1371/journal.pone.0175502.g001>

suspended in water (2000 mL) and extracted successively with petroleum ether (5×2000 mL), and EtOAc (5×2000 mL) to afford two organic fractions.

The extract of petroleum ether extract (50.0 g) was separated by column chromatography (CC) over silica gel, eluted with various petroleum ether-ethyl acetate gradients (50:1, 40:1, 30:1, 20:1, 15:1, 12:1, 10:1, 8:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 0:1, 3.6 L each) to yield 7 subfractions (Fr.1-Fr.7). Fr.2–6 were firstly subjected to MCI gel CC (80% ethanol) to remove pigments. Fr. 3 (petroleum ether-ethyl acetate 6:1, ca. 3.1g) was chromatographed over silica gel eluted with petroleum ether-ethyl acetate (13:1–3:1) to furnish **5** (50.1 mg). Fr.4 (petroleum ether-ethyl acetate 5:1, ca. 0.5 g) was chromatographed over Sephadex LH-20 eluting with dichloromethane-methanol (1:1) to yield **3** (10.4 mg). Fr.5 (petroleum ether-ethyl acetate 4:1–3:1, ca. 3.3 g) was submitted to silica gel CC eluted with petroleum ether-ethyl acetate (12:1–2:1) to yield Compound **1** (30.1 mg), **2** (12.3 mg).

The extract of EtOAc (32.8 g) was fractionated by column chromatography over silica gel eluting with petroleum ether followed by increasing concentration of ethyl acetate to yield 4 fractions (Fr.1-Fr.4). Fr.2 (petroleum ether-ethyl acetate 4:1–3:1, ca. 6.2g) was purified by silica gel CC eluted by petroleum ether-ethyl acetate (10:1–1:1) to give Compound **6** (9.4 mg), **9** (25.0mg). Fr.3 (petroleum ether-ethyl acetate 2:1, ca. 8.4g) was firstly fractionated to two sub-fractions (3a and 3b) by column chromatography over silica gel eluting with gradient elution (petroleum ether-ethyl acetate 5:1–1:1). Compound **7** (12.0mg) was derived from sub. 3a (3.2 g) by repeated CC with petroleum ether-ethyl acetate (2:1). The separation of sub.3b (2.3 g) separated over Sephadex LH-20 eluting with dichloromethane-methanol (1:1) to yield **8** (21.1 mg). Compound **4** (12.8 mg) was gained from Fr.4 (9.7 g, petroleum ether-ethyl acetate 1:1) which was subjected to CC over silica gel eluted with petroleum ether-ethyl acetate (4:1–1:2).

Compound characterization

3α -hydroxy- 19α -hydrogen-29-aldehyde-27-lupanoic acid (**1**): white amorphous powder, mp 201–202°C, purity 98.35%. $[\alpha]_{20}^D = -10.00$ ($c = 0.29$, MeOH). IR (KBr, max, cm^{-1}): 3640, 2949, 2862, 1718, 1237, 1215. ^1H and ^{13}C NMR (CHCl_3) (see Table 1). HR-ESI-MS: 495.3558 $[\text{M} + \text{Na}]^+$ ($[\text{C}_{30}\text{H}_{48}\text{O}_4 + \text{Na}]^+$, calc: 495.3553).

Table 1. ¹H and ¹³C NMR data of 1–3 at 400 and 100 MHz in CDCl₃ (δ in ppm; J in Hz).

Position	1		2		3	
	¹ H NMR	¹³ C NMR	¹ H NMR	¹³ C NMR	¹ H NMR	¹³ C NMR
1a	1.25 (1H, m)	33.22	1.28 (1H, m)	33.22	1.14 (1H, m)	33.84
1b	1.45 (1H, m)		1.48 (1H, m)		1.45 (1H, m)	
2a	1.58 (1H, m)	25.05	1.58 (1H, m)	25.03	1.58 (1H, m)	25.06
2b	1.72 (1H, m)		1.72 (1H, m)		1.72 (1H, m)	
3	3.42 (1H, t)	76.19	3.4 (1H, t)	76.16	4.61 (1H, t)	78.04
4		37.56		38.78		37.48
5	1.22 (1H, m)	48.95	1.20 (1H, m)	48.39	1.22 (1H, m)	49.25
6a	1.31 (1H, m)	18.17	1.35 (1H, m)	18.13	1.31 (1H, m)	18.05
6b	1.41 (1H, m)		1.43 (1H, m)		1.41 (1H, m)	
7a	1.32 (1H, m)	37.38	1.35 (1H, m)	37.48	1.35 (1H, m)	37.22
7b	1.46 (1H, m)		1.40 (1H, m)		1.41 (1H, m)	
8		40.77		42.55		40.8
9	1.28 (1H, m)	49.93	1.61 (1H, m)	50.7	1.28 (1H, m)	50.19
10		37.5		37.54		37.45
11a	1.32 (1H, m)	20.49	1.31 (1H, m)	20.62	1.32 (1H, m)	21.34
11b	1.59 (1H, m)		1.62 (1H, m)		1.59 (1H, m)	
12a	1.64 (1H, m)	27.25	1.64 (1H, m)	28.24	1.64 (1H, m)	27.15
12b	2.16 (1H, m)		2.16 (1H, m)		2.16 (1H, m)	
13	1.87 (1H, m)	38.74	1.81 (1H, m)	39.75	1.88 (1H, m)	38.88
14		60.26		60.26		60.16
15a	1.16 (1H, m)	23.51	1.16 (1H, m)	24.94	1.16 (1H, m)	23.53
15b	1.71 (1H, m)		1.71 (1H, m)		1.71 (1H, m)	
16a	1.61 (1H, m)	37.27	1.59 (1H, m)	37.48	1.61 (1H, m)	37.2
16b	1.69 (1H, m)		1.68 (1H, m)		1.69 (1H, m)	
17		42.37		42.66		42.31
18	1.56 (1H, m)	50.71	1.38 (1H, m)	51.38	1.57 (1H, m)	50.57
19	2.77 (1H, m)	49.31	2.77 (1H, m)	48.95	2.76 (1H, m)	50
20	2.42 (1H, m)	37.17	2.39 (1H, m)	37.09	2.43 (1H, m)	36.62
21a	1.58 (1H, m)	25.07	1.58 (1H, m)	25.21	1.58 (1H, m)	25.07
21b	1.72 (1H, m)		1.72 (1H, m)		1.72 (1H, m)	
22a	0.99 (1H, s)	40.33	0.99 (1H, s)	40.74	0.99 (1H, s)	40.35
22b	1.41 (1H, s)		1.41 (1H, s)		1.44 (1H, s)	
23	0.93 (3H, s)	28.31	0.93 (3H, s)	28.27	0.91 (3H, s)	27.71
24	0.83 (3H, s)	22.18	0.83 (3H, s)	22.18	0.84 (3H, s)	22.85
25	0.89 (3H, s)	16.54	0.90 (3H, s)	16.53	0.89 (3H, s)	16.53
26	1.13 (3H, s)	17.21	1.13 (3H, s)	17.24	1.15 (3H, s)	17.13
27		179.5		179.11		177.44
28	0.82 (3H, s)	18.42	0.79 (3H, s)	18.15	0.81 (3H, s)	18.42
29	9.63 (1H, s)	205.39	9.87 (1H, s)	207.52	9.87 (1H, s)	205.13
30	1.03 (3H, d, 7.29)	7.3	1.05 (3H, d, 7.29)	14.17	1.04 (3H, d, 6.84)	7.25
31						170.75
32					2.05 (3H, s)	20.39

<https://doi.org/10.1371/journal.pone.0175502.t001>

3α-hydroxy-19α-hydrogen-29-aldehyde-27-lupanoic acid (2): colorless acicular crystals, mp 200–201 °C, purity 99.10%. [α]_D²⁰ = -9.48 (c = 0.29, MeOH). IR (KBr, max, cm⁻¹): 3638, 2945, 2858, 1710, 1230, 1213. ¹H and ¹³C NMR (CHCl₃) (see Table 1). HR-ESI-MS: 495.3517 [M + Na]⁺ ([C₃₀H₄₈O₄ + Na]⁺, calc: 495.3553).

3 α -acetyl-19 α -hydrogen-29-aldehyde-27-lupanoic acid (**3**): white amorphous powder, mp 200–201°C, purity 96.35%. $[\alpha]_{20}^D = -9.06$ ($c = 0.29$, MeOH). IR (KBr, max, cm^{-1}): 3635, 2943, 2865, 1718, 1234, 1210. ^1H and ^{13}C NMR (CHCl_3) (see Table 1). HR-ESI-MS: 537.3481 $[\text{M} + \text{Na}]^+$ ($[\text{C}_{32}\text{H}_{50}\text{O}_5 + \text{Na}]^+$, calc: 537.3658).

In vitro cell cytotoxicity assay

The cytotoxic effects of Compounds **1–3** were estimated *in vitro* against HepG-2, MCF-7 and T-84 tumor cell lines by Cell Counting Kit-8 assay [28]. Briefly, the cells were seeded into 96-well plates in triplicate at an initial number of 5,000 cells per well and cultured at 37°C, 5% CO_2 for 24h, then treated with 0, 15, 20, 25, 30 μM of samples for another 24h. Ten microliters of the kit reagent was added to each well, and 2 h after all plates were scanned by a microplate reader (Thermo Fisher Scientific) at 450 nm. Cell cytotoxicity was calculated on the basis of absorbency.

Apoptosis analysis

The method for apoptosis analysis referred to the literature [29]. Apoptosis was discriminated with the annexin V-FITC/propidium iodide test. Cells were seeded at 3×10^5 /well in 10% FBS-DMEM into 6-well plates, and treated with Compound **1** with various concentrations. The cells were washed twice with cold Phosphate Buffered Saline (PBS) and then resuspended in $1 \times$ Binding Buffer (0.1 M HEPES/NaOH (pH 7.4), 1.4 M NaCl, 25 mM CaCl_2) at a concentration of 1×10^6 cells/mL. 100 μL of the solution (1×10^5 cells) was transferred to a 5 mL culture tube, and 5 μL of FITC Annexin V (BD, Pharmingen) and 5 μL of propidium iodide (PI) were added to each tube. The cells were gently vortexed and incubated at 25°C for 15 min in the dark. Then 200 μL of PBS was added to each tube. Analysis was performed with the system software (Cell Quest; BD Biosciences). The percentage of cells positive for PI and/or Annexin V-FITC was reported inside the quadrants. Lower left quadrant, viable cells (annexin V-/PI-); lower right quadrant, early apoptotic cells (annexin V+/PI-); upper right quadrant, late apoptotic cells (annexin V+/PI+); upper left quadrant, necrotic cells (annexin V-/PI+).

Hoechst 333258 staining

HepG-2 cells grown on a sterile cover slip in 6-well plates were treated with Compound **1** for 24 h. The culture medium containing Compound was removed, and the cells were fixed in 4% paraformaldehyde for 10 min. After two PBS washes, the cells were stained with 0.5 mL of Hoechst 33258 (Beyotime, Haimen, China) for 5 min and again two PBS washes. The stained nuclei were viewed using a Nikon ECLIPSETE2000-S fluorescence microscope (OLYMPUS Co., Japan) under 350 nm excitation and 460 nm emissions.

AO/EB staining

HepG-2 cells were seeded on a sterile cover slip in 6-well tissue culture plates at a concentration of 5×10^4 cell/mL in a volume of 2 mL. Following incubation, the medium was removed and replaced with fresh medium plus 10% fetal bovine serum and supplemented with concentrations of Compound **1** for 24 h. After the treatment period, the cover slip with monolayer cells was inverted on a glass slide with 10 μL of AO/EB stain (100 mg/mL). Fluorescence was read on a Nikon ECLIPSETE2000-S fluorescence microscope.

ROS assay

HepG-2 cells were seeded into 6-well plates for 24 h and subjected to various treatments. Then, the cells were cultured in a cell-free medium solution containing 10 mM DCFH-DA

(Beyotime, Haimen, China) at 37°C for 30 min in dark, and then with 3 times PBS washes. Cellular fluorescence was quantified under Nikon ECLIPSETE2000-S fluorescence microscope at 485 nm excitation and 538 nm emission.

Mitochondrial membrane potential staining

Mitochondrial depolarization was surveyed using cationic lipophilic dye JC-1 (Beyotime, Haimen, China) in MGC-803 cells. Briefly, cells were cultured with an equal volume of JC-1 staining solution (3 mg/mL) at 37°C for 20 min after incubated in 6-well plates and subjected to indicated treatments, and then washed twice with PBS. The changes in mitochondrial membrane potentials were measured by determining the relative amount of dual emissions from mitochondrial JC-1 monomers or aggregates using flow cytometry. Mitochondrial depolarization was identified by green/red fluorescence intensity ratio.

Western blot

HepG-2 cells were collected after treatments with Compound **1** (0, 15 and 30 μ M) for 24 h and then lysed in ice-cold RIPA buffer (1 \times PBS, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) which containing 100 μ g/mL PMSF, 5 μ g/mL Aprotinin, 5 μ g/mL Leupeptin, 5 μ g/mL Pepstatin and 100 μ g/mL NaF. After centrifugation at 12,000 rpm for 10 min, the protein in the supernatant was quantified by the Bradford method using Multimode varioscan instrument (Thermo Fischer Scientific). 30 μ g protein per lane was applied in 12% SDS polyacrylamide gel. After electrophoresis, the protein was transferred to a polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences). The membrane was blocked in TBST containing 5% blocking powder (Santacruz) at room temperature for 2 h. The membrane was washed with TBST for 5 min, and primary antibody (Bax, Bcl-2, cytochrome c, caspase-9, -3) was added and incubated at 4°C overnight (O/N). After three washes in TBST, the membrane was cultivated with corresponding horseradish peroxidase-labeled secondary antibody (1:20000) (Santa Cruz) at room temperature for 1 h. Membranes were rinsed with TBST for three times, 15 min each, and the protein blots were visualized with chemiluminescence reagent (Thermo Fischer Scientific Ltd.). The X-ray films were developed with developer and fixed with fixer solution.

Statistics

The data were processed by the Student's *t*-test with the significance level $p < 0.05$ and 0.01 using SPSS.

Results and discussion

Chemistry structures

Compound **1** was obtained as a white amorphous powder, $[\alpha]_{20}^D = -10.00$ ($c = 0.29$, MeOH). Its molecular formula was established as $C_{30}H_{48}O_4$ by HR-ESI-MS which showed an $[M + Na]^+$ ion peak at m/z 495.3558 (calculated for $[C_{30}H_{48}O_4 + Na]^+$: 495.3553), indicating 7 degrees of unsaturation.

There are six methyl group signals at δ 0.82, 0.83, 0.89, 0.93, 1.04, 1.13 in the 1H NMR spectrum and 30 carbon signals in ^{13}C NMR spectrum, which suggested that compound **1** was a triterpenoid [30]. δ_H 1.04 (d, 3H, $J = 7.29$) indicated that this methyl group coupled with a methine proton. The carbon signal at δ 205.39 and the proton signal at δ 9.63 exhibited one aldehyde group. Besides, a carboxyl group (δ_C 179.50) was clearly observed in NMR spectra data. The proton and carbon signals were shown in Table 1.




Fig 2. Structures and Key HMBC correlations (C→H) of Compound 1–3.

<https://doi.org/10.1371/journal.pone.0175502.g002>

A series of 2D NMR spectra were employed to further determine the structure of Compound **1**. H-19 (δ 2.77) correlated with C-19 (δ 49.95) in HSQC spectrum indicated that this compound was a lupane-triterpenoid [21]. Then, the carbon signal C-29 (δ 205.39) crossed with H-30 at δ 1.04 (3H, d, $J = 7.29$) and H-19 (δ 2.77); the correlations between C-30 (δ 7.30) and H-19 proved aldehyde group located at C-29 by HMBC spectrum. Next, it was confirmed that a carboxylic group located at C-14 rather than C-17 through the following evidences: the carboxyl carbon signal (δ 179.50) showed cross with H-13 (δ 1.87) and H-15 (δ 1.16 and δ 1.71); the quaternary carbon C-14 (δ 60.26) correlated with the protons at δ 1.13 (3H-26), δ 1.87 (H-13) and δ 1.56 (H-18); the methyl signal of C-28 (δ 18.42) exhibited cross peaks with H-18 (δ 1.56) and H-22 (δ 1.41). After that, an oxygen-bearing methine proton at δ 3.42 (t, 1H) correlated with the carbon signal at δ 76.19 confirmed that a hydroxyl was attached to the structure (HSQC), what's more, the hydroxyl was located at C-3 according the HMBC cross-peaks of the proton δ 3.42 with C-23 (δ 28.31) and C-24 (δ 22.18). Key HMBC correlations were shown in Fig 2. Thus, the planar structure of **1** was determined as 3-hydroxy-29-aldehyde-27-lupanoic acid.

The relative configuration of **1** was determined by a ROESY experiment. All chiral centers were assumed to be consistent with (20s)-3 α , 29-dihydroxylupan-27-oic acid [21]. The ROESY correlation of H-3/H₃-24/H₃-26/H-13/H β -16/H₃-28 indicated these protons were β -orientation. In addition, the cross of H-19/H α -16 proved H-19 was α -equatorial and the isopropylaldehyde group located at C-19 was β -orientation (Fig 3). On the basis of the above results, the structure **1** was deduced as 3 α -hydroxy-19 α -hydrogen-29-aldehyde-27-lupanoic acid.

Compound **2** was isolated as a colorless acicular crystal, $[\alpha]_{20}^D = -9.48$ ($c = 0.29$, MeOH). Its molecular formula was assigned to be C₃₀H₄₈O₄ on the basis of the HR-ESI-MS, which gave an $[M + Na]^+$ ion peak at m/z 495.3517 (calculated for $[C_{30}H_{48}O_4 + Na]^+$: 495.3553).

Similar to compound **1**, the NMR spectra data of **2** showed the characteristic signals of six methyl groups, an aldehyde group, a carboxyl group and a hydroxyl group. And the planar structure of **2** had been proved by HSQC and HMBC spectra, which was the same as the previous one (Table 1; Fig 2). However, its carbon chemical shifts of C-29 (δ 14.17) and C-30 (δ 207.52) were quite different with that of compound **1** (C-29 at δ 7.30 and C-30 at δ 205.39). Furthermore, the ROESY cross of H-19/H β -16 proved that the isopropylaldehyde group at C-19 was α -orientation, which was different from Compound **1** (H19/H α -16).




Fig 3. Key ROESY correlations of Compound 1–3.

<https://doi.org/10.1371/journal.pone.0175502.g003>

Hence, the structure **2** was identified as 3α -hydroxy- 19β -hydrogen-29-aldehyde-27-lupanoic acid.

Compound **3** was obtained as a white amorphous powder with $[\alpha]_{20}^D = -9.06$ ($c = 0.29$, MeOH). Its molecular formula, $C_{32}H_{50}O_5$, was established by ^{13}C NMR and HR-ESI-MS (m/z 537.3481 $[M + Na]^+$, calculated for $[C_{32}H_{50}O_5 + Na]^+$, 537.3658) data, corresponding to eight indices of hydrogen deficiency.

The assigned NMR data of **3** were in Table 1. A proton signal at δ 9.64 together with the carbon signal at δ 205.13 helped to testify the aldehyde group, which was quite similar with Structure **1**. However, in Compound **3**, seven methyl group signals were clearly observed in the 1H -NMR spectra, besides, two carbonyl groups were found based on the carbon signals at δ 170.75 and δ 177.44. In HMBC, the signal (δ_H 2.05 (s, 3H) correlated with δ_C 170.75) indicated that an acetyl group was attached to the structure (Fig 2). Moreover, the fact of a methine proton at δ 4.61 (t, 1H) correlated with C-23 (δ 27.71) and C-24 (δ 22.85) confirmed that the acetyl was located at C-3 (HMBC), which substituted the hydroxyl group of Compound **1**. The ROESY correlation of H-3/H₃-24/H₃-25/H₃-26/H-13/H β -16/H₃-28 indicated these protons were β -orientation; the cross of H-19/H α -16 proved H-19 was α -equatorial, which was similar to Compound **1** (Fig 3). Based on these results, structure **3** was assigned as 3α -acetyl- 19α -hydrogen-29-aldehyde-27-lupanoic acid.

Compounds **4–9** were identified by comparing their spectrum data with literature values as follows: tormentic acid (**4**) [31]; ursolic acid (**5**) [32]; Betulinic acid (**6**) [33]; 3', 3'', 4'-tri-O-methylellagic acid (**7**) [34]; Luteolin (**8**) [35]; Quercetin (**9**) [36].

Evaluation of antitumor activities

Quite a number of triterpenoids with different structures have been confirmed to be antitumor agents. In the past few years, plenty of literatures about pentacyclic triterpenoids with potent anti-cancer activities were published [37]. It is well-known that the inhibition on cancer proliferation has been a continuous effort in cancer treatment. Therefore, *in vitro* cytotoxicity of Compounds **1–3** were evaluated by CCK-8 assay against HepG-2, MCF-7 and T-84 cell lines, with matrine as a positive control as shown in Table 2. Compound **1** demonstrated strong activities against HepG-2 cell line with IC_{50} value of 17.84 μM , comparable to the positive control (matrine) with IC_{50} value of 30.88 μM , while it exhibited moderate cytotoxic activities for the other two cell lines with IC_{50} values 30.78 (MCF-7) and 27.89 (T-84) μM , respectively. Compound **2** showed similar activities to Compound **1**, with IC_{50} values of 18.21, 30.99 and 27.87 μM , respectively; Compound **3** exhibited relatively weaker cytotoxicity for MCF-7 (IC_{50} 35.43 μM), and the lowest cytotoxicity for T-84 (IC_{50} 40.64 μM).

Table 2. Cytotoxicity (IC₅₀) of Compounds 1, 2 and 3 (n = 3).

Sample	Cytotoxicity (IC ₅₀ , μM)		
	HepG-2	MCF-7	T-84
1	17.84±1.21**	30.78±1.88*	27.89±1.96*
2	18.21±1.94**	30.99±1.83*	27.87±0.99*
3	25.32±1.87*	35.43±1.52	40.64±3.64**
Matrine^a	30.88±2.28	35.54±2.92	32.81±2.95

^a Positive control;

* and**, Significant difference between Compound and Matrine by *t*-test at *p* < 0.05 and 0.01, respectively.

<https://doi.org/10.1371/journal.pone.0175502.t002>

With the investigation, we found that Compound **1** and **2** exhibited pretty similar activities against all these three cell lines (Table 2, S1 Table), suggesting that the change of isopropyl aldehyde configuration has little effect on the antitumor activity. Meanwhile, Structure **1–3** all displayed higher resistance to HepG-2 cell line which indicate that specific differences in chemical structure with a carboxyl group at C-14 have an influence on the cytotoxic properties and proliferation of HepG-2 cell line (Table 2, *p* < 0.05 and 0.01). What is interesting is that this result was similar to the previously reported by Sun *et al.* [38], who discovered that an oleanane-type triterpene with a carboxyl group at C-14 from *Astilbe chinensis* could significantly inhibit on the proliferation of HeLa cells and induce cell apoptosis. In particular, although Compound **3** also showed activity against HepG-2, its inhibition level was much lower than that of Compound **1** (S1 Table, *p* < 0.01). In view of these differences of the two structures, it can be concluded that hydroxyl group could be more important for the enhanced cytotoxic activity than acetyl.

Due to its well cytotoxic inhibition on HepG-2, the inhibition activities of Compound **1** against HL-7702 normal human liver cell line were also assayed (Fig 4a). With respect to cell viability, above 90% HL-7702 cells were survival even when the concentration of Compound **1** was 35 μM. In contrast, with the improvement of sample concentration, the cell viability of HepG-2 gradually decreased, with only a survival rate of 9.50% when treated with Compound **1** at a concentration of 35 μM. These results indicated that **1** showed low cytotoxicity on normal human liver cell line HL-7702, on the contrary high *in vitro* antiproliferative activity on the cancer cell lines, which indicated that the targeted compounds had selective and significant effect on the HepG-2 cell lines.

Effects of Compound 1 on the induction of apoptosis

A reduction in cell growth and induction in cell death are two major means to inhibit tumor growth [39]. Apoptosis is a complex physiological process that permits the reduction of harmful or unnecessary cells during development, tissue homeostasis and disease. To confirm whether Compound **1** induced reduction in cell viability due to the induction of apoptosis, the apoptotic rates of HepG-2 cells treated with Compound **1** at various concentrations of 0, 15, 20, 25, 30 μM for 24 h were determined in present work (Fig 4b–4f). It was observed that Compound **1** significantly caused cell apoptosis at both early and late stages. Specifically, compared with control (3.06%, 4.26%), the early and late apoptosis rates were gradually increased from (6.96%, 4.27%), (16.14%, 10.61%) to (20.05%, 14.30%) and (23.69%, 22.93%) after treatment at 15, 20, 25, 30 μM for 24h, respectively. These results provided evidence that Compound **1** could cause a notable increase of cellular apoptosis in a dose-dependent manner from 0 to 30 μM.




Fig 4. (a) Effects of Compound 1 on human hepatocellular carcinoma cell line (HepG-2) and normal liver cell line (HL-7702). (b-f) Apoptosis analysis of HepG-2 cells treated with compound 1 at various concentrations of 0, 15, 20, 25, 30 μM, respectively.

<https://doi.org/10.1371/journal.pone.0175502.g004>

Hoechst 33258 and AO/EB staining

To further validate cell apoptosis upon treatment of Compound 1, HepG-2 cells were stained with Hoechst 33258 and AO/EB staining after the treatment for 24 h at different concentrations (0, 15 and 30 μM). Hoechst 33258 is a membrane permeable blue fluorescent dye which stains the cell nucleus. Under fluorescence microscope, live cells exhibited uniformly light blue nuclei after treatment with Hoechst 33258, while apoptotic cells had bright blue nuclei because of karyopyknosis and chromatin condensation, besides dead cells' nuclei could not be stained. Our observation showed that most of the normal cells exhibited weak blue fluorescence in the control group (Fig 5). While in the treatment group with 1, apoptotic cells increased gradually




Fig 5. Hoechst 33258 staining of HepG-2 cells treated with Compound 1. (a) HepG-2 cells without Compound 1 treatment were used as control and (b, c) HepG-2 cells treated with Compound 1 (15 μ M and 30 μ M) for 24 h, respectively.

<https://doi.org/10.1371/journal.pone.0175502.g005>

in a dose-dependent manner and exhibited typical changes including reduction of cellular volume, bright staining and condensed or fragmented nuclei.

Apoptosis was further evaluated using acridine orange/ethidium bromide (AO/EB) double staining, which differentiates between necrosis and apoptosis by the difference in membrane integrity. AO is a vital dye which can pass through cell membranes of living or early apoptotic cells, while EB can only stain cells that had lost their membrane integrity. In our research, the cytotoxicity of Compound 1 at 15 and 30 μ M for 24 h treatment against HepG-2 cells was detected by AO/EB staining, and cells treated without 1 were used as control. As shown in Fig 6, cells treated with compound at different concentrations had obviously changed. The nuclei were stained as yellow green, the morphology showed pycnosis. These findings also confirmed that Compound 1 was able to induce apoptosis, which consistent with the results of Hoechst 33258 staining.

Intracellular ROS level in HepG-2 cells induced by Compound 1

Reactive oxygen species (ROS) are highly harmful elements to cells as they initiate oxidative stress and ultimately cause cellular damage. Excessive ROS generation renders cells vulnerable to apoptosis [40, 41]. Several studies have shown that natural pentacyclic triterpenes trigger a




Fig 6. AO/EB staining of HepG-2 cells treated with Compound 1. (a) Not treated with Compound 1 were used as control and (b, c) treatment with Compound 1 (15 μ M and 30 μ M) for 24 h, respectively.

<https://doi.org/10.1371/journal.pone.0175502.g006>




Fig 7. Compound 1 increased the intracellular ROS level of HepG-2 cells. (a) Increase of ROS level in HepG-2 cells showing a concentration dependent manner. (b) ROS levels in HepG-2 cells expressed as units of MFI were calculated as a percentage of the control.

<https://doi.org/10.1371/journal.pone.0175502.g007>

rapid production of intracellular ROS, which might be responsible for their cytotoxic actions [42, 43]. To determine whether **1** triggers ROS generation in HepG-2 cells to induce apoptosis, the ROS level in the cells with or without **1** treatment was measured using 2,7-dichlorofluorescein diacetate (DCF-DA) as fluorescent probe by flow cytometry. As shown in Fig 7, the results showed that Compound **1** induced an increase of ROS level in HepG-2 cells. After exposure to 15 μM Compound **1** for 24 h, the ROS level increased to 23.5%, more than two times higher than that of control (10.6%). Even further ROS level increased to 46.8% when treated with **1** at the concentration of 30 μM for 24 h. Taken together, these results indicate that Compound **1** can cause the oxidative imbalance in HepG-2 cells. This induction of oxidative burst is a key factor behind the anti-proliferative activity of Compound **1**.

Mitochondrial membrane potential ($\Delta\Psi_m$) in HepG-2 cells

The loss of $\Delta\Psi_m$ is regarded as a limiting factor in the apoptotic pathway. To further investigate the apoptosis-inducing effect of target compound, changes of mitochondrial membrane potential were detected using the fluorescent probe JC-1, which can easily pass through the plasma membrane into cells and accumulates in mitochondria [44]. As indicated in Fig 8, the treatment of HepG-2 cells with Compound **1** at different concentrations for 24h led to the loss of $\Delta\Psi_m$. After exposed to 15 and 30 μM target compound for 24 h, $\Delta\Psi_m$ was reduced to 69.1% and 49.4% of control, respectively, in a dose-dependent manner. The experimental results demonstrated that depolarization of mitochondria were occurred after treated with Compound **1**.

Release of cytochrome c and activation of caspases were involved in the apoptosis induced by Compound 1

Mitochondrial pathway, which is connected with the loss of $\Delta\Psi_m$ in most of times, is one of the major ways to induce cellular apoptosis. Because the loss of $\Delta\Psi_m$ has been suggested to




Fig 8. Compound 1 decreased the $\Delta\Psi_m$ level of HepG-2 cells. (a, b, c) Decrease of the $\Delta\Psi_m$ level in HepG-2 cells showing a dose-dependent manner.

<https://doi.org/10.1371/journal.pone.0175502.g008>

cause the release of cytochrome c from the mitochondria to the cytosol, which is a limiting factor in the mitochondrial pathway. To confirm the molecular mechanisms involved in the observed apoptosis, we investigated the effects of Compound 1 on the expression of proteins related with mitochondria mediated apoptosis. In Fig 9a, the cytochrome c level in the cytosol was gradually improved when treated with Compound 1 at concentrations of 0, 15 and 30 μM , most probably due to the release of mitochondrial cytochrome c. At the same time, it is well-known that mitochondrial apoptotic pathway is regulated by the Bcl-2 family of pro- and anti-apoptotic proteins, which stimulate the permeabilization of the mitochondrial outer




Fig 9. Compound 1 treatment led to the activation of cytochrome c, Bax, Bcl-2, caspase-9 and caspase-3. Densitometric analysis of western blot results of panel (a), and the results are shown in (b). The results were expressed as the mean \pm SEM of three experiments ($p < 0.05$).

<https://doi.org/10.1371/journal.pone.0175502.g009>

membrane and cytochrome c released into the cytosol, promoting in the activation of the caspase cascade and induction of apoptotic cell death [45, 46]. As shown in Fig 9, compared with the control group, **1** induced a significant increase of Bax level and an inhibition on the expression of Bcl-2, in a dose-dependent manner. Cytochrome c is reportedly involved in the activation of downstream caspases that trigger apoptosis, so these results indicated that caspases are involved in the apoptotic process downstream of mitochondria. In this study, we examined the roles of important caspases (caspase-9 and -3) in the cellular response to Compound **1**. Western blot analysis showed that treatment of HepG-2 cells with **1** significantly induced cleavage of caspase-9 and -3. These results revealed that caspases are involved in the intrinsic apoptotic process downstream of mitochondria. From the above, Compound **1** induced HepG-2 cells apoptosis possibly by decreasing the activation of Bcl-2 and stimulating its downstream proteins associated with mitochondria-dependent apoptotic pathway.

Plants used in traditional medicine, ethnomedicine, folk medicine and herbalism provide a rational and obvious source of candidates for the targeted identification of lead substances. In this study, all nine compounds were classified into three categories: triterpenes (**1–6**), phenols (**7**) and flavonoids (**8, 9**). Three new compounds were found rarely, although six known structures occur widely in majority of the botanical taxa. Combined with other studies, some ellagic acid derivatives are considered to be useful taxonomic markers for this genus and triterpenoids are the main substances isolated from the *Potentilla* species [15, 16]. For this reason, several more recent phytochemical studies have concentrated on the isolation of triterpenoid structures from *Potentilla* species, comprising *Potentilla erecta*, *Potentilla anserine*, *Potentilla multicaulis* and *Potentilla discolor*. These compounds are usually based on pentacyclic triterpene skeleton [16], which represent a very powerful class of natural products due to their broad biological activity and amazing diversity of structures [25]. It is well-known that lupane-triterpenoids are considered as a particularly important series of pentacyclic triterpenoids, and they abundantly occur in the plant kingdom and other organisms. Whereas, to the best of our knowledge, the lupane-triterpenoids showing the presence of a carboxyl group at C-14 position is present in a limited number of natural resources. So far, sporadic C-27-carboxylated-pentacyclic triterpenoids have been obtained from saxifragaceae plants [27, 38, 47]. In fact, as mentioned before, Yang *et al.* [21] isolated two new lupane-triterpenoids from the whole herbs of PD with their C-27 position were highly oxygenated. Combined with the previous work, PD may be used as another important resource for these markable compounds.

Cancer has become one of leading cause of unnatural death globally. Over the ten decades, the development of antineoplastic drugs has greatly attracted scientists' interest. In fact, at least 60% of anticancer agents originate from natural compounds [48]. Meanwhile, diabetes mellitus can lead to serious harm to human health like cancer [49]. Encouragingly, it was proved by Han *et al.* [47] that the pentacyclic triterpenoids substituted with a carboxylic acid at the C-27 position isolated from *Astilbe rivularis* can enhance glucose uptake, suggesting that C-27-carboxylated-pentacyclic triterpenoids may serve as scaffolds for development as agents for the management of blood glucose levels in disease states such as diabetes. Thus, all these observations confirmed that C-27-carboxylated-pentacyclic triterpenoids has a crucial effect on human health of two major killers.

Conclusion

The present study revealed that three novel C-27-carboxylated-lupane-triterpenoids were isolated from *Potentilla discolor* Bunge, which were found rarely in nature. 3 α -hydroxy-19 α -hydrogen-29-aldehyde-27-lupanoic acid was confirmed that it had a selective and distinctive cytotoxicity toward HepG-2 cells, which supported the previous conclusion that the position

of carboxyl group affects the cytotoxicity of pentacyclic triterpenes. Meanwhile, 3 α -hydroxy-19 α -hydrogen-29-aldehyde-27-lupanoic acid could cause a marked increase of HepG-2 cellular apoptosis in a dose-dependent manner. The further mechanisms of apoptosis demonstrated that this compound might decrease the activation of Bcl-2 and stimulate its downstream proteins which are associated with the mitochondria-dependent apoptotic pathway. All these results should be useful in the search for new potential antitumor agents and for developing semisynthetic lupane-triterpenoid derivatives with antitumor activities.

Supporting information

S1 Fig. ¹H NMR spectrum of Compound 1.

(TIF)

S2 Fig. ¹³C NMR spectrum of Compound 1.

(TIF)

S3 Fig. HSQC spectrum of Compound 1.

(TIF)

S4 Fig. HMBC spectrum of Compound 1.

(TIF)

S5 Fig. ROESY spectrum of Compound 1.

(TIF)

S6 Fig. HR-ESI-MS of Compound 1.

(TIF)

S7 Fig. ¹H NMR spectrum of Compound 2.

(TIF)

S8 Fig. ¹³C NMR spectrum of Compound 2.

(TIF)

S9 Fig. HSQC spectrum of Compound 2.

(TIF)

S10 Fig. HMBC spectrum of Compound 2.

(TIF)

S11 Fig. ROESY spectrum of Compound 2.

(TIF)

S12 Fig. HR-ESI-MS of Compound 2.

(TIF)

S13 Fig. ¹H NMR spectrum of Compound 3.

(TIF)

S14 Fig. ¹³C NMR spectrum of Compound 3.

(TIF)

S15 Fig. HSQC spectrum of Compound 3.

(TIF)

S16 Fig. HMBC spectrum of Compound 3.

(TIF)

S17 Fig. ROESY spectrum of Compound 3.

(TIF)

S18 Fig. HR-ESI-MS of Compound 3.

(TIF)

S19 Fig. HPLC of Compound 1.

(TIF)

S20 Fig. HPLC of Compound 2.

(TIF)

S21 Fig. HPLC of Compound 3.

(TIF)

S1 Table. Cytotoxicity (IC₅₀) comparison of Compounds 1, 2 and 3 at pair (n = 3).

(TIF)

Acknowledgments

This study was supported by State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Guangxi Normal University) (CMEMR2016-B06), the Priority Academic Program Development of Jiangsu Higher Education Institutions (No. 1107047002), and the Taishan Overseas Talents Introduction Program of Shandong, China (No. tshw20120747).

Author Contributions

Conceptualization: ZXL JYS.

Data curation: JZ RZH.

Formal analysis: JZ.

Funding acquisition: ZXL JYS.

Investigation: JZ CL HFC.

Methodology: JZ CL XKX.

Project administration: ZXL JYS.

Resources: FXW.

Software: JZ.

Supervision: ZXL JYS.

Validation: ZXL JYS.

Visualization: JZ.

Writing – original draft: JZ.

Writing – review & editing: JZ.

References

1. Chaoluan L, Ikeda H, Ohba H. *Potentilla* Linnaeus, Sp. Pl. 1: 495. 1753. In: Flora of China 9; 2003. pp. 291–327. www.efloras.org/.

2. USDA-ARS. National Genetic Resources Program. Germplasm Resources Information Network—(GRIN) [Online Database]. National Germplasm Resources Laboratory, Beltsville, Maryland. 2008. <http://www.ars-grin.gov/cgi-bin/npgs/html/explist.pl>.
3. Manandhar NP. A survey of medicinal plants of Jajarkot district, Nepal. *J Ethnopharmacol.* 1995; 48: 1–6. PMID: [8569241](#)
4. McCutcheon AR, Roberts TE, Gibbons E, Ellis SM, Babiuk LA, Hancock REW, et al. Antiviral screening of British Columbian medicinal plants. *J Ethnopharmacol.* 1995; 49: 101–110. PMID: [8847882](#)
5. Chen K, Plumb GW, Bennett RN, Bao Y. Antioxidant activities of extracts from five anti-viral medicinal plants. *J Ethnopharmacol.* 2005; 96: 201–205. <https://doi.org/10.1016/j.jep.2004.09.020> PMID: [15588671](#)
6. Spiridonov NA, Konovalov DA, Arkhipov VV. Cytotoxicity of some Russian ethnomedicinal plant compounds. *Phytother Res.* 2005; 19: 428–432. <https://doi.org/10.1002/ptr.1616> PMID: [16106386](#)
7. Tosun A, Bahadır Ö, Altanlar N. Antimicrobial activity of some plants used in folk medicine in Turkey. *Turk J Pharm Sci.* 2006; 3: 167–176.
8. Webster D, Taschereau P, Belland RJ, Sand C, Rennie RP. Antifungal activity of medicinal plant extract; preliminary screening studies. *J Ethnopharmacol.* 2008; 115: 140–146. <https://doi.org/10.1016/j.jep.2007.09.014> PMID: [17996411](#)
9. European Pharmacopoeia 9.0. Monograph of *Tormentillae rhizoma* and *Tormentillae tincture*; 2017. pp. 1542.
10. Chinese Pharmacopoeia, Volume I. Monograph of *Potentilla discolor*; 2015. pp. 383.
11. Editorial Committee of Chinese Flora. *Flora of China*. Science Press, Beijing; 1985. pp. 291.
12. Jiangsu New Medical College. *Dictionary of Chinese Material Medica*. Shanghai Scientific and Technical Publishers, Shanghai; 1975. pp. 2705–2706.
13. Li J, Zhou f, Zhang Z. *Medica Flora of Shandong*. Xi'an Jiaotong University Press, Xi'an; 2013. pp. 283–284.
14. Meng L, Zhu L, Zheng H, Gu C, Cai X. Effect of PDB on hyperglycemic animal models. *Chin Pharm Bull.* 2004; 20: 588–590.
15. Xue P, Zhao Y, Wang B, Liang H. Secondary metabolites from *Potentilla discolor* Bunge (Rosaceae). *Biochem Syst Ecol.* 2006; 34: 825–828.
16. Tomczyk M, Latté KP. *Potentilla*-A review of its phytochemical and pharmacological profile. *J Ethnopharmacol.* 2009; 122: 184–204. <https://doi.org/10.1016/j.jep.2008.12.022> PMID: [19162156](#)
17. Jin Q, Nan J, Lian L. Antitumor activity of leaves from *Potentilla discolor* on Human Hepatocellular Carcinoma Cell Line HepG-2. *Chin J Nat Med.* 2011; 9: 0061–0064.
18. Xue P, Yin T, Liang H, Zhao Y. Study on chemical constituents of *Potentilla discolor*. *Chin Pharm J.* 2005; 40: 1052–1054.
19. Jang DS, Kim JM, Lee GY, Kim JH, Kim JS. Ursane-type triterpenoids from the aerial parts of *Potentilla discolor*. *Agr Chem Biotechnol.* 2006; 49: 48–50.
20. Jang DS, Yoo NH, Kim JM, Lee YM, Yoo JL, Kim JS. An ellagic acid rhamnoside from the roots of *Potentilla discolor* with protein glycation and rat lens aldose reductase inhibitory activity. *Nat Prod Sci.* 2007; 13: 160–163.
21. Yang J, Chen X, Liu X, Cao Y, Lai M, Wang Q. Structural determination of two new triterpenoids from *Potentilla discolor* Bunge by NMR techniques. *Magn Reson Chem.* 2008; 46: 794–797. <https://doi.org/10.1002/mrc.2253> PMID: [18509870](#)
22. Konoshima T, Takasaki M, Tokuda H, Masuda K, Araj Y, Shiojima K, et al. Anti-tumor-promoting activities of triterpenoids from ferns. I. *Biol Pharm Bull.* 1996; 19: 962–965. PMID: [8839970](#)
23. Wada S, Tanaka R, Iida A, Matsunaga S. *In Vitro* inhibitory effects of DNA topoisomerase II by fernane-Type triterpenoids isolated from a *Euphorbia* genus. *Bioorg Med Chem Lett.* 1998; 8: 2829–2832. PMID: [9873631](#)
24. Cheng L, Shen L, Zhang M, Li N, Li X, Ma Z, et al. Eleven new triterpenes from *Eurycorymbus cavaleriei*. *Helv Chim Acta.* 2010; 93: 2263–2276.
25. Hill RA, Connolly JD. Triterpenoids. *Nat Prod Rep.* 2012; 29: 780–818. <https://doi.org/10.1039/c2np20027a> PMID: [22592567](#)
26. Liu C, Liao Z, Liu S, Ji L, Sun H. Two new 2, 3-Seco-Hopane Triterpene Derivatives from *Megacodon stylophorus* and their antiproliferative and antimicrobial activities. *Planta Med.* 2014; 80: 936–941. <https://doi.org/10.1055/s-0034-1368612> PMID: [24995501](#)
27. Lu M, Liao Z, Ji L, Sun H. Triterpenoids of *Chrysosplenium carnosum*. *Fitoterapia.* 2013; 85: 119–124. <https://doi.org/10.1016/j.fitote.2013.01.006> PMID: [23352747](#)

28. Tang J, Tao Z, Wen D, Wan J, Liu D, Zhang S, et al. miR-612 suppresses the stemness of liver cancer via Wnt/ β -catenin signaling. *Biochem Bioph Res Co.* 2014; 447: 210–215.
29. Hua S, Huang R, Ye M, Pan Y, Yao G, Zhang Y, et al. Design, synthesis and *in vitro* evaluation of novel ursolic acid derivatives as potential anticancer agents. *Eur J Med Chem.* 2015; 95: 435–452. <https://doi.org/10.1016/j.ejmech.2015.03.051> PMID: 25841199
30. Connolly JD, Hill RA. Triterpenoids. *Nat. Prod. Rep.* 1996; 16: 151–169.
31. Mei Z, Chen X, Xia X, Fang Z, Zhou H, Gao Y, et al. Isolation and chemotaxonomic significance of chemical constituents from *Rubus parvifolius*. *Chin Herbal Med* 2016; 8: 75–79.
32. Ibrahim M, Ambreen S, Hussain A, Hussain N, Imran M, Ali B, et al. Phytochemical investigation on *Eucalyptus globulus* Labill. *Asian J Chem.* 2014; 26: 1011–1014.
33. Zhang N, Li N, Sun YN, Li JL, Xing SS, Tuo ZD, et al. Diacylglycerol compounds from Barks of *Betula platyphylla* with inhibitory activity against acyltransferase. *Chin Herb Med.* 2014; 6: 164–167.
34. Khac DD, Tran-Van S, Campos AM, Lallemand JY, Fetizon M. Ellagic compounds from *Diplopanax stachyanthus*. *Phytochem.* 1990; 29: 251–256.
35. Li YL, Li J, Wang NL, Yao XS. Flavonoids and a new polyacetylene from *Bidens parviflora* Willd. *Molecules.* 2008; 13: 1931–1941. PMID: 18794794
36. Zhang ZL, Zuo YM, Xu L, Qu XS, Luo YM. Studies on chemical components of flavonoids in aerial part of *Saururus chinensis*. *Chin Tradit Herb Drugs.* 2011; 42: 1490–1493.
37. Ovesná Z, Vachálková A, Horváthová K, Tóthová D. Pentacyclic triterpenoic acids: new chemoprotective compounds. *Minireview. Neoplasma.* 2004; 51: 327–333. PMID: 15640935
38. Sun HX, Zheng QF, Tu J. Induction of apoptosis in Hela cells by 3 β -hydroxy-12-oleanen-27-oic acid from the rhizomes of *Astilbe chinensis*. *Bioorg Med Chem.* 2006; 14: 1189–1198. <https://doi.org/10.1016/j.bmc.2005.09.043> PMID: 16214353
39. Park WH, Cho YH, Jung CW, Park JO, Kim K, Im YH, et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. *Biochem Bioph Res Co.* 2003; 300: 230–235.
40. Zhang JY, Wu HY, Xia XK, Liang YJ, Yan YY, She ZG, et al. Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive oxygen species-independent mitochondrial pathway and death receptor pathway. *Cancer Biol Ther.* 2007; 6: 1413–1421. PMID: 17786034
41. Quan Z, Gu J, Dong P, Lu J, Wu W, Fei X, et al. Reactive oxygen species-mediated endoplasmic reticulum stress and mitochondrial dysfunction contribute to cisimarin-induced apoptosis in human gallbladder carcinoma GBC-SD cells. *Cancer Lett.* 2010; 295: 252–259. <https://doi.org/10.1016/j.canlet.2010.03.008> PMID: 20359814
42. Martín R, Carvalho-Tavares J, Ibeas E, Hernandez M, Ruiz-Gutierrez V, Nieto ML. Acidic triterpenes compromise growth and survival of astrocytoma cell lines by regulating reactive oxygen species accumulation. *Cancer Res.* 2007; 67: 3741–3751. <https://doi.org/10.1158/0008-5472.CAN-06-4759> PMID: 17440087
43. Prasad S, Yadav VR, Kannappan R, Aggarwal BB. Ursolic acid, a pentacyclic triterpene, potentiates TRAIL-induced apoptosis through p53-Independent upregulation of death receptors: Evidence for the role of reactive oxygen species and C-Jun N-terminal kinase. *J Biol Chem.* 2011; 286: 5546–5557. <https://doi.org/10.1074/jbc.M110.183699> PMID: 21156789
44. Garner DL, Thomas CA. Organelle-specific probe JC-1 identifies membrane potential differences in the mitochondrial function of bovine sperm. *Mol Rep Dev.* 1999; 53: 222–229.
45. Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. *Apoptosis.* 2002; 7: 313–319. PMID: 12101390
46. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, et al. Apoptosis and cancer: mutations within caspase genes. *Med Genet.* 2009; 46: 497–510.
47. Han JH, Zhou W, Li W, Tuan PQ, Khoi NM, Thuong PT, et al. Pentacyclic triterpenoids from *Astilbe rivularis* that enhance glucose uptake via the activation of Akt and Erk1/2 in C2C12 myotubes. *J Nat Prod.* 2015; 78: 1005–1014. <https://doi.org/10.1021/np5009174> PMID: 25894669
48. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. *J Nat Prod.* 2012; 75: 311–335. <https://doi.org/10.1021/np200906s> PMID: 22316239
49. Oikonomakos NG. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. *Curr Protein Pept Sc.* 2002; 3: 561–586.